{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:11:24Z","timestamp":1789726284835,"version":"4.0.1"},"reference-count":35,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s368590","type":"journal-article","created":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T03:15:12Z","timestamp":1680923712000},"page":"1097-1106","source":"Crossref","is-referenced-by-count":28,"title":["Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions"],"prefix":"10.2147","volume":"Volume 17","author":[{"given":"Tiffany","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8582-5831","authenticated-orcid":true,"given":"Ben","family":"Alencherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Ospina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0010-9797","authenticated-orcid":true,"given":"Milind Y","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"ref2","unstructured":"Administration FD. Approved drug proucts: CAMZYOS (mavacamten) capsules for oral use; 2022."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMra1710575","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1161\/CIRCGENETICS.116.001620","volume":"10","author":"Ingles","year":"2017","journal-title":"Circ Cardiovasc Genet"},{"key":"ref5","first-page":"e558","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu199","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/phar.1664","volume":"35","author":"Verlinden","year":"2015","journal-title":"Pharmacotherapy"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamacardio.2016.0252","volume":"1","author":"Kim","year":"2016","journal-title":"JAMA Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s40256-022-00532-x","volume":"22","author":"Edelberg","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","volume":"49","author":"Grillo","year":"2019","journal-title":"Xenobiotica"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","volume":"292","author":"Kawas","year":"2017","journal-title":"J Biol Chem"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1080\/13543784.2020.1821361","volume":"29","author":"Tower-Rader","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.7326\/M18-3016","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e009627","DOI":"10.1161\/JAHA.118.009627","volume":"7","author":"Mamidi","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e0168407","DOI":"10.1371\/journal.pone.0168407","volume":"11","author":"Stern","year":"2016","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"A10969","DOI":"10.1161\/circ.144.suppl_1.10969","volume":"144","author":"Semigran","year":"2021","journal-title":"Circulation"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/S0735-1097(21)01891-X","volume":"77","author":"Rader","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","volume":"80","author":"Milind","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","volume":"76","author":"Ommen","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"ref24","unstructured":"FDA approves new drug to improve heart function in adults with rare heart condition [press release]. FDA.gov; 2022."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","volume":"78","author":"Dybro","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"ref26","unstructured":"Bristol-Myers Squibb. Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER 2018 https:\/\/ClinicalTrials.gov\/show\/NCT03496168. 2 August 2022 April 12."},{"key":"ref27","unstructured":"Bristol-Myers Squibb. A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM 2018 https:\/\/ClinicalTrials.gov\/show\/NCT03723655 2 August 2022 October 29"},{"key":"ref28","unstructured":"Cytokinetics REDWOOD-HCM: Randomized Evaluation of Dosing With CK-3773274 in HCM 2020 https:\/\/ClinicalTrials.gov\/show\/NCT04219826 3 August 2022 January 7."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1016\/j.amjmed.2017.12.031","volume":"131","author":"Wells","year":"2018","journal-title":"Am J Med"},{"key":"ref30","first-page":"10600280221117812","volume":"2022","author":"Dalo","year":"2022","journal-title":"Ann Pharmacother"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Beinfeld M. Mavacamten for hypertrophic cardiomyopathy: effectiveness and value; 2022.","DOI":"10.18553\/jmcp.2022.28.3.369"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.cardfail.2022.03.345","volume":"28","author":"Patel","year":"2022","journal-title":"J Card Fail"},{"key":"ref34","unstructured":"Bristol-Myers Squibb A study of mavacamten in participants with HFpEF and elevation of NT-proBNP with or without elevation of cTnT (EMBARK-HFpEF) 2021 https:\/\/ClinicalTrials.gov\/show\/NCT04766892 2 August 2022 February 23."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.mayocp.2014.01.025","volume":"89","author":"Bos","year":"2014","journal-title":"Mayo Clin Proc"}],"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=88836","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=88836","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T03:15:19Z","timestamp":1680923719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/review-of-mavacamten-for-obstructive-hypertrophic-cardiomyopathy-and-f-peer-reviewed-fulltext-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":35,"URL":"https:\/\/doi.org\/10.2147\/dddt.s368590","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]}}}